Search

The GnRH-A therapy is the treatment of choice for CPP, with the main objective to increase height potential, which is compromised by the premature fusion of growth cartillages. We assessed in a retrospective longitudinal unicenter study the impact of treatment with GnRH-A on growth velocity, SDSh, SDS ba, the final height and eventual adverse effects in 18 girls with idiopathic CPP. We follow-up in a long-term study, from 1992 until 2003, 16 girls with CPP, treated by Decapeptyl-Depot or Diferilin Depot, in dose of 3,75 mg every 28 days. Duration of treatment was from 1y 11mo to 8y 8mo. The middle age of onset of PP was 3,17, the age of diagnosis - 3,78 and the age of therapy 6,25. The diagnosis was based on clinical and paraclinical parameters like the degree of thelarche and pubarche, SDSh, SDSba, growth velocity (which were rapidly progressing), the positive LH-RH test.The results of the treatment were good. The accelerated growth velocity decreased as well as SDSh an SDSba, degree of thelarche and pubarche fall dawn.There was positive correlation between SDSh at the onset of therapy and the height in the end of observation, which was about 10 cm bellow the midparental height. At the end of observation and after cessation of the treatment, gradually the pubertal symptoms developed again. After cessation of the therapy, menses appeared in an interval of 10 mo to 2 yrs. The GnRH-A treatment appears to improve height potential, especially when PP is diagnosed and the therapy begins before the age of 6 and SDSh is not very high.The growth outcomes and the real final height, after pubertal growth spurt, would be better [ABSTRACT FROM AUTHOR]